Neurocrine Biosciences | NBIX - Sales Revenues


Neurocrine Biosciences reported $811M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Repligen USD 194M 3.91M Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026